134 related articles for article (PubMed ID: 38324946)
21. Cortical thickness in clinical moyamoya disease: A magnetic resonance imaging study.
Tompkins G; Levman J; Ijner P; Shiohama T; Takahashi E
Int J Dev Neurosci; 2021 Dec; 81(8):698-705. PubMed ID: 34370351
[TBL] [Abstract][Full Text] [Related]
22. Proximal internal carotid artery stenosis associates with diffuse wall thickening in petrous arterial segment of moyamoya disease patients: a three-dimensional magnetic resonance vessel wall imaging study.
Chen X; Wang J; Liu Y; Yang Y; Zhou F; Li X; Zhang B; Zhao X
Neuroradiology; 2019 Jan; 61(1):29-36. PubMed ID: 30402746
[TBL] [Abstract][Full Text] [Related]
23. Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography.
Schwartz E; Cruickshank FA; Lebwohl M
Exp Mol Pathol; 1990 Feb; 52(1):63-8. PubMed ID: 2307214
[TBL] [Abstract][Full Text] [Related]
24. Determination of free desmosine in human plasma and its application in two experimental medicine studies.
Lamerz J; Friedlein A; Soder N; Cutler P; Döbeli H
Anal Biochem; 2013 May; 436(2):127-36. PubMed ID: 23399390
[TBL] [Abstract][Full Text] [Related]
25. Dilated perivascular spaces and steno-occlusive changes in children and adults with moyamoya disease.
Park MG; Roh J; Ahn SH; Cho JW; Park KP; Baik SK
BMC Neurol; 2024 Jan; 24(1):14. PubMed ID: 38166838
[TBL] [Abstract][Full Text] [Related]
26. Assessment of plasma soluble Tie-2 level to distinguish moyamoya disease from atherosclerotic cerebrovascular disease and predict postoperative neovascularization.
Chen T; Wei W; Zhang J; Yu J; Xu S; Wu D; Li X; Chen J
J Neurosurg; 2023 Dec; 139(6):1705-1714. PubMed ID: 37347656
[TBL] [Abstract][Full Text] [Related]
27. Quantitative high-performance liquid chromatography-tandem mass spectrometry method for the analysis of free desmosines in plasma and urine.
Miliotis T; Lindberg C; Semb KF; van Geest M; Kjellström S
J Chromatogr A; 2013 Sep; 1308():73-8. PubMed ID: 23953714
[TBL] [Abstract][Full Text] [Related]
28. Isotope-dilution LC-MS/MS analysis of the elastin crosslinkers desmosine and isodesmosine in acute cerebral stroke patients.
Mikagi A; Tashiro R; Inoue T; Anzawa R; Imura A; Tanigawa T; Ishida T; Inoue T; Niizuma K; Tominaga T; Usuki T
RSC Adv; 2022 Nov; 12(49):31769-31777. PubMed ID: 36380946
[TBL] [Abstract][Full Text] [Related]
29. Impact of Endothelial Shear Stress on the Bilateral Progression of Unilateral Moyamoya Disease.
Lee WJ; Jeong SK; Han KS; Lee SH; Ryu YJ; Sohn CH; Jung KH
Stroke; 2020 Mar; 51(3):775-783. PubMed ID: 31856692
[TBL] [Abstract][Full Text] [Related]
30. Effect of revascularization on cognitive outcomes in intracranial steno-occlusive disease: a systematic review.
Kolb B; Fadel H; Rajah G; Saber H; Luqman A; Rangel-Castilla L
Neurosurg Focus; 2019 Feb; 46(2):E14. PubMed ID: 30717064
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 7.0- and 3.0-T MRI and MRA in ischemic-type moyamoya disease: preliminary experience.
Deng X; Zhang Z; Zhang Y; Zhang D; Wang R; Ye X; Xu L; Wang B; Wang K; Zhao J
J Neurosurg; 2016 Jun; 124(6):1716-25. PubMed ID: 26544772
[TBL] [Abstract][Full Text] [Related]
32. Imaging of Moyamoya Disease and Moyamoya Syndrome: Current Status.
Li J; Jin M; Sun X; Li J; Liu Y; Xi Y; Wang Q; Zhao W; Huang Y
J Comput Assist Tomogr; 2019; 43(2):257-263. PubMed ID: 30589721
[TBL] [Abstract][Full Text] [Related]
33. More Precise Imaging Analysis and Diagnosis of Moyamoya Disease and Moyamoya Syndrome Using High-Resolution Magnetic Resonance Imaging.
Yu LB; He H; Zhao JZ; Wang R; Zhang Q; Shi ZY; Shao JS; Zhang D
World Neurosurg; 2016 Dec; 96():252-260. PubMed ID: 27576769
[TBL] [Abstract][Full Text] [Related]
34. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis?
Kaku Y; Morioka M; Ohmori Y; Kawano T; Kai Y; Fukuoka H; Hirai T; Yamashita Y; Kuratsu J
Acta Neurochir (Wien); 2012 Dec; 154(12):2151-7. PubMed ID: 22935819
[TBL] [Abstract][Full Text] [Related]
35. Moyamoya disease: a summary.
Burke GM; Burke AM; Sherma AK; Hurley MC; Batjer HH; Bendok BR
Neurosurg Focus; 2009 Apr; 26(4):E11. PubMed ID: 19335127
[TBL] [Abstract][Full Text] [Related]
36. Flow-augmentation bypass for moyamoya disease.
Fujimura M; Tominaga T
J Neurosurg Sci; 2021 Jun; 65(3):277-286. PubMed ID: 33245218
[TBL] [Abstract][Full Text] [Related]
37. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for moyamoya disease.
Sonobe S; Fujimura M; Niizuma K; Nishijima Y; Ito A; Shimizu H; Kikuchi A; Arai-Ichinoi N; Kure S; Tominaga T
Brain Res; 2014 Mar; 1552():64-71. PubMed ID: 24440776
[TBL] [Abstract][Full Text] [Related]
38. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation.
Ma S; Turino GM; Lin YY
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1893-8. PubMed ID: 21621489
[TBL] [Abstract][Full Text] [Related]
39. High-performance liquid chromatographic quantitation of desmosine plus isodesmosine in elastin and whole tissue hydrolysates.
Soskel NT
Anal Biochem; 1987 Jan; 160(1):98-104. PubMed ID: 3105350
[TBL] [Abstract][Full Text] [Related]
40. Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the R4859K mutation of RNF213, the susceptibility gene for moyamoya disease.
Kanoke A; Fujimura M; Niizuma K; Ito A; Sakata H; Sato-Maeda M; Morita-Fujimura Y; Kure S; Tominaga T
Brain Res; 2015 Oct; 1624():497-505. PubMed ID: 26315378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
